CALR and essential thrombocythemia: The most frequent molecular mutation present in myeloproliferative neoplasms is the JAK2V617F mutation present in more than 95% of PV patients and 50–60% of ET and PMF patients, followed by CALR mutations and MPL mutations, respectively [55,56,57,58,59].